Genetic blueprint vs. standard care: which fights spreading cancer better?

This study is testing whether choosing cancer drugs based on the unique genetic changes found in a patient's tumor is more effective at controlling the disease than standard treatment. It involves over 1,300 people with metastatic cancer, meaning cancer that has spread. Patients are randomly assigned to receive either a 'matched' targeted therapy or their doctor's choice of standard care to see which approach keeps the cancer from worsening longer.